ChemInform Abstract: Copper Catalyzed C-N Bond Formation via a Sequential Acylation and Deacylation Process: A Novel Strategy for the Synthesis of Benzanilides.

ChemInform ◽  
2015 ◽  
Vol 46 (26) ◽  
pp. no-no
Author(s):  
Saurabh Kumar ◽  
Rajeshwer Vanjari ◽  
Tirumaleswararao Guntreddi ◽  
Krishna Nand Singh
Keyword(s):  
Bond Formation ◽  
Novel Strategy

Hybrid nanomaterials for asymmetric purposes: green enantioselective C–C bond formation by chiralization and multi-functionalization approaches

2020 ◽  
Vol 10 (24) ◽  
pp. 8240-8253 ◽  
Author(s):  
Sayed Ali Akbar Razavi ◽  
Kayhaneh Berijani ◽  
Ali Morsali
Keyword(s):  
Bond Formation ◽  
Hybrid Nanomaterials ◽  
Hybrid Nanomaterial ◽  
Novel Strategy

We present a simple and novel strategy for synthesis of a MOF-based chiral multi-functional hybrid nanomaterial through chiralization and multi-functionalization approaches for asymmetric purposes.

Copper catalysed C–N bond formation via a sequential acylation and deacylation process: a novel strategy for the synthesis of benzanilides

RSC Advances ◽  
2015 ◽  
Vol 5 (13) ◽  
pp. 9920-9924 ◽  
Author(s):  
Saurabh Kumar ◽  
Rajeshwer Vanjari ◽  
Tirumaleswararao Guntreddi ◽  
Krishna Nand Singh
Keyword(s):  
Bond Formation ◽  
Copper Catalysis ◽  
Novel Strategy ◽  
Oxidative Amidation

An efficient oxidative amidation of aldehydes using acetanilides as amine component has been developed by copper catalysis. The approach is versatile and proceeds through sequential acylation and deacylation to afford benzanilides.

scholarly journals Iodine-mediated C–N and N–N bond formation: a facile one-pot synthetic approach to 1,2,3-triazoles under metal-free and azide-free conditions

RSC Advances ◽  
2019 ◽  
Vol 9 (46) ◽  
pp. 27021-27031 ◽  
Author(s):  
Geeta Sai Mani ◽  
Kavitha Donthiboina ◽  
Siddiq Pasha Shaik ◽  
Nagula Shankaraiah ◽  
Ahmed Kamal
Keyword(s):  
Transition Metal ◽  
Bond Formation ◽  
Synthetic Approach ◽  
One Pot ◽  
Metal Free ◽  
Novel Strategy

A novel strategy towards the synthesis of 1,4-disubstituted 1,2,3-triazoles via C–N and N–N bond formation has been demonstrated under transition metal-free and azide-free conditions.

Transition-metal-free oxidative carboazidation of acrylamides via cascade C–N and C–C bond-forming reactions

2014 ◽  
Vol 12 (25) ◽  
pp. 4329-4334 ◽  
Author(s):  
Jun Qiu ◽  
Ronghua Zhang
Keyword(s):  
Free Radical ◽  
Transition Metal ◽  
Efficient Method ◽  
Bond Formation ◽  
Cascade Process ◽  
Metal Free ◽  
Bond Forming ◽  
Bond Forming Reactions ◽  
Radical Cascade ◽  
Novel Strategy

A novel transition-metal-free oxidative carboazidation of acrylamides using inexpensive NaN3 and K2S2O8 was achieved, which not only provided an efficient method to prepare various N3-substituted oxindoles, but also represented a novel strategy for C–N and C–C bond formation via a free-radical cascade process.

Transition-metal-free halocarbocyclisation of acrylamides using K2S2O8

2017 ◽  
Vol 41 (6) ◽  
pp. 352-357 ◽  
Author(s):  
Haiwei Ye ◽  
Liping Zhou ◽  
Yunhua Chen ◽  
Jun Qiu
Keyword(s):  
Transition Metal ◽  
Bond Formation ◽  
Direct Transition ◽  
Metal Free ◽  
Novel Strategy

A novel and direct transition-metal-free oxidative halocarbocyclisation of acrylamides using inexpensive KX (X = I, Br, Cl) and K2S2O8 has been developed. This methodology not only provides an efficient way to construct valuable halogenated oxindoles in good to excellent yields, but also represents a novel strategy for C–X and C–C bond formation.

The Collaborative Network Approach: a model for advancing patient-centric research for Castleman disease and other rare diseases

2019 ◽  
Vol 3 (1) ◽  
pp. 97-105
Author(s):  
Mary Zuccato ◽  
Dustin Shilling ◽  
David C. Fajgenbaum
Keyword(s):  
Rare Diseases ◽  
Treatment Options ◽  
Castleman Disease ◽  
High Impact ◽  
Collaborative Network ◽  
Network Approach ◽  
Grant Applications ◽  
Research Questions ◽  
Novel Strategy ◽  
Patient Centric

Abstract There are ∼7000 rare diseases affecting 30 000 000 individuals in the U.S.A. 95% of these rare diseases do not have a single Food and Drug Administration-approved therapy. Relatively, limited progress has been made to develop new or repurpose existing therapies for these disorders, in part because traditional funding models are not as effective when applied to rare diseases. Due to the suboptimal research infrastructure and treatment options for Castleman disease, the Castleman Disease Collaborative Network (CDCN), founded in 2012, spearheaded a novel strategy for advancing biomedical research, the ‘Collaborative Network Approach’. At its heart, the Collaborative Network Approach leverages and integrates the entire community of stakeholders — patients, physicians and researchers — to identify and prioritize high-impact research questions. It then recruits the most qualified researchers to conduct these studies. In parallel, patients are empowered to fight back by supporting research through fundraising and providing their biospecimens and clinical data. This approach democratizes research, allowing the entire community to identify the most clinically relevant and pressing questions; any idea can be translated into a study rather than limiting research to the ideas proposed by researchers in grant applications. Preliminary results from the CDCN and other organizations that have followed its Collaborative Network Approach suggest that this model is generalizable across rare diseases.

Sign in / Sign up

Export Citation Format

Share Document